Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.77
Price to sales ratio
7.65

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4493
SNTI
Senti Biosciences, Inc. - Common Stock
0.96 USD-6.80%-11.93%-1.03%+0.84%29.90 M USD
4497
KYNB
Kyntra Bio, Inc. - Common Stock
7.34 USD-4.80%-1.87%+4.11%-22.82%29.71 M USD
4505
ATNM
Actinium Pharmaceuticals, Inc. Common Stock
0.91 USD-3.19%-5.21%-10.78%-12.50%28.55 M USD
4520
BTAI
BioXcel Therapeutics, Inc. - Common Stock
0.88 USD+7.32%-20.72%-24.14%-44.30%27.17 M USD

Frequently asked questions about PLUS THERAPEUTICS, Inc. - Common Stock

What is the PLUS THERAPEUTICS, Inc. - Common Stock stock price today?

The current price of PLUS THERAPEUTICS, Inc. - Common Stock (PSTV) is 4.17. Over the past 24 hours, the stock has changed by +4.25%. Follow the PSTV chart for real-time price dynamics.

What is the stock ticker of PLUS THERAPEUTICS, Inc. - Common Stock?

PLUS THERAPEUTICS, Inc. - Common Stock trades under the ticker PSTV. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is PLUS THERAPEUTICS, Inc. - Common Stock stock going up?

PSTV has changed by +3.73% over the last week, -18.40% over the last month, and +1163.64% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was PLUS THERAPEUTICS, Inc. - Common Stock net income for the last quarter?

PLUS THERAPEUTICS, Inc. - Common Stock reported net income of -6.95 M for the last quarter. The previous quarter showed -5.71 M, which means net income changed by -21.58%.

How many employees does PLUS THERAPEUTICS, Inc. - Common Stock have?

As of the latest available data, PLUS THERAPEUTICS, Inc. - Common Stock has 28 employees. Workforce size can provide additional context about the company's scale and operations.

What is PLUS THERAPEUTICS, Inc. - Common Stock EBITDA?

PLUS THERAPEUTICS, Inc. - Common Stock EBITDA is -7.02 M, and its EBITDA margin is -683.17%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy PLUS THERAPEUTICS, Inc. - Common Stock stock?

You can buy PLUS THERAPEUTICS, Inc. - Common Stock (PSTV) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in PLUS THERAPEUTICS, Inc. - Common Stock stock?

Investing in PLUS THERAPEUTICS, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the PSTV chart and related analysis on metatrader.com as part of your research.

PLUS THERAPEUTICS, Inc. - Common Stock

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.

News